Business
Pluristem Therapeutics Inc. Announces Proposed Public Offering of Common Stock and Warrants and Concurrent Registered Direct Offering of Common Stock
HAIFA, Israel, April 03, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) ("Pluristem" or "Company"), a leading regenerative
About this update from Pluri Inc.
[{"type":"text","content":"HAIFA, Israel, April 03, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) (\"Pluristem\" or \"Company\"), a leading regenerative medicine company developing novel placenta-based cell therapy product candidates, announced today that it intends to offer and sell shares of its common stock and warrants in an underwritten public offering and shares of its common stock in a concurrent registered direct offering. All of the shares and warrants in the underwritten public offering, and the shares in the concurrent registered direct offering, are to be sold by Pluristem. Pluristem intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and/or warrants offered in the public offering at the public offering price, less the underwriting discounts and commissions.The Company intends to use the net proceeds of both offerings for research and product development activities, clinical trial activities, investment in capital equipment and for working capital and other general corporate purposes.Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE American:LTS), is acting as sole book running manager in connection with the underwritten public offering and as placement agent in the registered direct offering. Both offerings are subject to market and other conditions, and there can be no assurances as to whether or when the offerings may be completed, or as to the actual size or terms of the offerings.The shares of common stock and warrants offered in the underwritten public offering and the shares of common stock offered in the registered direct offering described above are being offered by Pluristem pursuant to its shelf registration statement on Form S-3 (File No. 333-218916) previously filed and declared effective by the Securities and Exchange Commission (the \"SEC\") on June 30, 2017. The offerings may be made only by means of a prospectus supplement and accompanying prospectus. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the underwritten public offering may be obtained from Ladenburg Thalmann & Co. Inc., Prospectus Department, 277 Park Ave, 26th Floor, New York, NY 10172, by calling (212) 409-2000, or by email at [email protected] press r...